Abstract
SURVIVAL OUTCOMES AND RISK FACTORS IN PATIENTS WITH STAGE IIIC–IV OVARIAN CARCINOMA TREATED WITH NEOADJUVANT BEVACIZUMAB COMBINED WITH PACLITAXEL–CARBOPLATIN CHEMOTHERAPY AT HANOI ONCOLOGY HOSPITAL
Objective: To evaluate survival outcomes and identify prognostic factors in patients with stage IIIC–IV ovarian carcinoma treated with neoadjuvant bevacizumab plus paclitaxel–carboplatin chemotherapy at Hanoi Oncology Hospital.
Methods: A descriptive study analyses of 36 patients with stage IIIC–IV ovarian carcinoma treated with neoadjuvant bevacizumab plus paclitaxel–carboplatin chemotherapy at Hanoi Oncology Hospital from 2022 to 2024
Results: Medium progression - free survival time was 18.3 ± 2.34 months, the at 2 - year progression-free survival rate was estimated at 29.5%. Residual tumor burden following surgery was significantly associated with progression-free survival (p = 0.001). Patients who achieved complete cytoreduction experienced the longest medium progression-free survival, reaching 33.2 months. In contrast, age, disease stage, and histological subtype were not significantly associated with progression-free survival.
Conclusion: Neoadjuvant bevacizumab plus paclitaxel–carboplatin chemotherapy has shown positive survival results in patients with stage IIIC–IV ovarian carcinoma. Residual tumor burden following surgery has been an important factor affecting survival outcome.
Keywords: Ovarian carcinoma, neoadjuvant, stage IIIC-IV, bevacizumab, survival outcome.
References
Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-63.
Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, et al. Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer. New England Journal of Medicine. 2010;363(10):943-53.
Garcia Garcia Y, de Juan Ferré A, Mendiola C, Barretina-Ginesta MP, Gaba Garcia L, Santaballa Bertrán A, et al. Efficacy and safety results from GEICO 1205, a randomized phase II trial of neoadjuvant chemotherapy with or without bevacizumab for advanced epithelial ovarian cancer. Int J Gynecol Cancer. 2019;29(6):1050-6.
Rouzier R, Gouy S, Selle F, Lambaudie E, Floquet A, Fourchotte V, et al. Efficacy and safety of bevacizumab-containing neoadjuvant therapy followed by interval debulking surgery in advanced ovarian cancer: Results from the ANTHALYA trial. Eur J Cancer. 2017;70:133-42.
Kehoe S, Hook J, Nankivell M, Jayson GC, Kitchener H, Lopes T, et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet. 2015;386(9990):249-57.
Vergote I, Coens C, Nankivell M, Kristensen GB, Parmar MKB, Ehlen T, et al. Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials. Lancet Oncol. 2018;19(12):1680-7.
Elattar A, Bryant A, Winter-Roach BA, Hatem M, Naik R. Optimal primary surgical treatment for advanced epithelial ovarian cancer. Cochrane Database Syst Rev. 2011;2011(8):Cd007565.
| Published | 18-08-2026 | |
| Fulltext |
|
|
| Language |
|
|
| Issue | Vol. 18 No. 5 (2026) | |
| Section | Original article | |
| DOI | 10.38103/jcmhch.18.5.7 | |
| Keywords | Từ khóa: Ung thư buồng trứng, điều trị tân bổ trợ, giai đoạn IIIC-IV, bevacizumab, thời gian sống thêm. |
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2026 Journal of Clinical Medicine Hue Central Hospital